Literature DB >> 25305357

A prospective, randomized, controlled trial of the treatment of anterior vaginal wall prolapse: medium term followup.

José Tadeu Nunes Tamanini1, Renata Cristina de Oliveira Souza Castro2, Juliana Milhomem Tamanini3, Rodrigo Aquino Castro4, Marair Gracio Ferreira Sartori4, Manoel João Batista Castello Girão4.   

Abstract

PURPOSE: We compared the efficacy and safety of anterior colporrhaphy with transvaginal polypropylene mesh insertion for anterior vaginal wall prolapse at medium term followup.
MATERIALS AND METHODS: In this prospective, randomized, controlled trial 100 women with stage II or greater anterior vaginal wall prolapse assessed by POP-Q were randomized to anterior colporrhaphy (controls) or mesh insertion. Anatomical outcomes were assessed by POP-Q measurement and prolapse stage. Subjective outcomes and quality of life impact were evaluated by ICIQ questionnaires. We evaluated the procedure safety profile according to intraoperative complication rates throughout followup.
RESULTS: In the mesh and control groups 42 and 50 women completed the 24-month followup. Point Ba did not significantly differ between the groups at baseline but at 24-month followup it had significantly improved in the mesh group compared to controls. However, no difference was found between the groups when considering 2 cure criteria on prolapse stage and subjective parameters. Asymptomatic mesh exposure developed on the anterior vaginal wall prolapse in 7 patients (16.4%) in the mesh group. Minor mesh related complications consisted of mesh exposure, prepubic ecchymosis and groin pain, of which most were treated conservatively. Urinary retention was treated surgically.
CONCLUSIONS: Nazca TC™ and anterior colporrhaphy provided good overall anatomical outcomes during a minimum 24-month followup. Vaginal and urinary symptoms, and quality of life improved postoperatively in each group. From the patient perspective Nazca TC did not show superior overall outcomes compared to anterior colporrhaphy performed with or without a retropubic sling.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cystocele; female; pelvic organ prolapse; surgical mesh; urinary bladder

Mesh:

Year:  2014        PMID: 25305357     DOI: 10.1016/j.juro.2014.10.003

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

Review 1.  The treatment of anterior vaginal wall prolapsed by repair with mesh versus colporrhaphy.

Authors:  Yi Sun; Cai Tang; Deyi Luo; Lu Yang; Hong Shen
Journal:  Int Urol Nephrol       Date:  2015-12-19       Impact factor: 2.370

Review 2.  The efficacy of pelvic floor muscle training for pelvic organ prolapse: a systematic review and meta-analysis.

Authors:  Chunbo Li; Yuping Gong; Bei Wang
Journal:  Int Urogynecol J       Date:  2015-09-25       Impact factor: 2.894

Review 3.  Assessing the use of the IUGA/ICS classification system for prosthesis/graft complications in publications from 2011 to 2015.

Authors:  Emily English; Megan Solomon; Bertha Chen; Lisa Rogo-Gupta
Journal:  Int Urogynecol J       Date:  2016-06-01       Impact factor: 2.894

Review 4.  Current surgical management of pelvic organ prolapse: Strategies for the improvement of surgical outcomes.

Authors:  Kwang Jin Ko; Kyu-Sung Lee
Journal:  Investig Clin Urol       Date:  2019-10-29

Review 5.  Current trends and future perspectives in pelvic reconstructive surgery.

Authors:  Mélanie Aubé; Le Mai Tu
Journal:  Womens Health (Lond)       Date:  2018 Jan-Dec

6.  A systematic review of outcome and outcome-measure reporting in randomised trials evaluating surgical interventions for anterior-compartment vaginal prolapse: a call to action to develop a core outcome set.

Authors:  Constantin M Durnea; Vasilios Pergialiotis; James M N Duffy; Lina Bergstrom; Abdullatif Elfituri; Stergios K Doumouchtsis
Journal:  Int Urogynecol J       Date:  2018-10-22       Impact factor: 2.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.